74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
TG Therapeutics Inc
Closed
SectorHealthcare
36.61 0.36
Overview
Share price change
24h
Min
36.04
Max
36.89
Income | 23M 28M |
|---|---|
Sales | 20M 141M |
P/E Sector Avg | 94.436 35.739 |
Profit margin | 19.97 |
Employees | 370 |
EBITDA | 25M 38M |
Recommendations | Neutral |
|---|---|
12 Months Forecast | +4.62% upside |
Next Earnings | 3 Nov 2025 |
|---|
Market Cap | 1.3B 5.8B |
|---|---|
Previous open | 36.25 |
Previous close | 36.61 |
News Sentiment
By Acuity
67%
33%
334 / 371 Healthcare
Technical Score
By Trading Central
Confidence
Very Strong Bearish Evidence
TG Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
TG Therapeutics Inc Forecast
Price Target
By TipRanks
4.62% upside
12 Months Forecast
Average 38.25 USD 4.62%
High 55 USD
Low 11 USD
Based on 4 Wall Street analysts offering 12 month price targets forTG Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
334 / 371 Healthcare
News Sentiment
Bearish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About TG Therapeutics Inc
TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
Live chat